COVID – 19 LATEST UPDATES
SEQENS mobilizes its innovation to support the unprecedented research on the covid-19 and prepares its unique industrial network for anti-virus production, for…
Read moreProtéus by Seqens’ team has recently developed and produced a highly efficient enzyme. It is operated for the biocatalytic production of…
Read moreDuring the last 5 years, large price increases were observed for precious transition metal catalysts: Palladium price has increased by a factor…
Read moreSugar-reduction in food is at the heart of everyone’s concerns. Fructo OligoSaccharides (FOS) are a natural sweet-tasting, low-calorie alternative that is widely…
Read moreProtéus-By-Seqens team, located in Nîmes (France), is pleased to announce having achieved the “Gold” level following the evaluation of its Corporate Social…
Read moreThis year, the Pierre Potier 2020 prize was awarded to Protéus by Seqens, the group’s biotech subsidiary specialized in enzymatic biocatalysis,…
Read moreOn July 27th, during the Protein Engineering Congress USA, Protéus by Seqens gave a talk on « Biocatalysis from lab to industrial scale », right…
Read moreREPLAY OF THE WEBINAR About BIOCATALYSIS On May 6th, Proteus by Seqens co-organized, together with the French bioeconomy cluster IAR a webinar on…
Read moreengineering of enzymatic cascades from D-serine This special issue highlights innovative organic chemistry research from academic and industrial chemists across France and its…
Read moreEfficient and safe process design combining SEQENS technical capabilities: Brilacidin as a case study As already mentioned in our previous article (“Seqens…
Read moreFocusing on biocatalysis for asymmetric synthesis and precious metal catalysts replacement The covid-19 crisis triggered an unprecedented mobilization of pharmaceutical research. Mid-April, 440…
Read more